These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Glintborg D; Højlund K; Andersen M; Henriksen JE; Beck-Nielsen H; Handberg A Diabetes Care; 2008 Feb; 31(2):328-34. PubMed ID: 18000176 [TBL] [Abstract][Full Text] [Related]
44. Role of metformin in patients with polycystic ovary syndrome: the state of the art. Palomba S; Falbo A; Russo T; Orio F; Tollino A; Zullo F Minerva Ginecol; 2008 Feb; 60(1):77-82. PubMed ID: 18277354 [TBL] [Abstract][Full Text] [Related]
45. Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome. Skov V; Glintborg D; Knudsen S; Jensen T; Kruse TA; Tan Q; Brusgaard K; Beck-Nielsen H; Højlund K Diabetes; 2007 Sep; 56(9):2349-55. PubMed ID: 17563058 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome. Al-Ozairi E; Quinton R; Advani A Fertil Steril; 2008 Oct; 90(4):1197.e1-4. PubMed ID: 18222436 [TBL] [Abstract][Full Text] [Related]
47. Metformin in polycystic ovary syndrome. Targher G; Lippi G; Moghetti P N Engl J Med; 2008 Apr; 358(17):1867; author reply 1868. PubMed ID: 18437728 [No Abstract] [Full Text] [Related]
48. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Wang ZJ; Liu Q; Li PP; Zou CH; Shen ZF Eur J Pharmacol; 2008 Feb; 580(1-2):277-83. PubMed ID: 18048028 [TBL] [Abstract][Full Text] [Related]
49. Use of metformin in polycystic ovary syndrome. Mathur R; Alexander CJ; Yano J; Trivax B; Azziz R Am J Obstet Gynecol; 2008 Dec; 199(6):596-609. PubMed ID: 19084097 [TBL] [Abstract][Full Text] [Related]
50. The use of metformin as first line treatment in polycystic ovary syndrome. Abbas M; Gannon M Ir Med J; 2008 Feb; 101(2):51-3. PubMed ID: 18450250 [TBL] [Abstract][Full Text] [Related]
51. Polycystic ovary syndrome. Homburg R Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):261-74. PubMed ID: 17804299 [TBL] [Abstract][Full Text] [Related]
53. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Lydic ML; McNurlan M; Bembo S; Mitchell L; Komaroff E; Gelato M Fertil Steril; 2006 Jul; 86(1):243-6. PubMed ID: 16730719 [TBL] [Abstract][Full Text] [Related]
54. We should avoid the indiscriminate use of insulin sensitizers in women with polycystic ovary syndrome. Azziz R Fertil Steril; 2003 Aug; 80(2):264-5. PubMed ID: 12909483 [No Abstract] [Full Text] [Related]
55. Widding the Use of Insulin Sensitizers to Patients with Polycystic Ovarian Syndrome-A Late, but Wise Decision. Silva de Sá MF Rev Bras Ginecol Obstet; 2019 Mar; 41(3):137-141. PubMed ID: 30991430 [No Abstract] [Full Text] [Related]
56. Hyperandrogenemia associated with insulin resistance mimicking an androgen producing tumor. Nichelson E; Toffle RC W V Med J; 2002; 98(2):61-2. PubMed ID: 12048740 [TBL] [Abstract][Full Text] [Related]